GPP
TBPH icon

Great Point Partners’s Theravance Biopharma TBPH Stock Holding History

Great Point Partners’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-824,580
Closed -$14.7M – 36
2020
Q4 		$14.7M Buy
+824,580
New +$14.8M 2.38% 17

Other funds holding TBPH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Great Point Partners's TBPH Position: Q1 2021 in Review

Great Point Partners sold out of Theravance Biopharma (TBPH) in Q1 2021, closing a stake of 824,580 shares — an estimated $14.7M sold.

Great Point Partners first reported a position in TBPH in Q4 2020 and held it in 1 quarter. The position peaked at $14.7M in Q4 2020. 107 funds tracked by Wall St. Rank hold TBPH as of Q1 2021.

  • Great Point Partners reported no remaining Theravance Biopharma position as of Q1 2021 after selling out during the quarter.
  • Great Point Partners sold 824,580 Theravance Biopharma shares in Q1 2021, an estimated $14.7M.
  • Great Point Partners first reported a position in Theravance Biopharma in Q4 2020 and held it in 1 quarter.
  • Great Point Partners's Theravance Biopharma position peaked at $14.7M in Q4 2020.
  • 107 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2021.

Based on Great Point Partners's 13F filing for Q1 2021, filed 17 May 2021.